Pexidartinib and Hepatic Impairment

In this article, we will discuss Pexidartinib and Hepatic Impairment. So, let’s get started.

Pexidartinib and Hepatic Impairment

No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin less than or equal to upper limit of normal [ULN] with AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN with any AST).

The recommended dose of pexidartinib has not been established for patients with
moderate (total bilirubin greater than 1.5 to 3 times ULN and any AST) to severe (total
bilirubin greater than 3 to 10 times ULN and any AST) hepatic impairment.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.